Clinical Trials at Ingalls Memorial
Our goal is to provide the highest level of care to all of our patients, and that includes offering novel treatments before they are widely available. If you are a cancer patient, you may be eligible for one of our current clinical trials.
Adenoid Cystic Carcinoma
- Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR trial
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Bile Duct Cancer
- Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physician’s Choice in Subjects with FGFR-altered, Chemotherapy and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Bladder Cancer
- Stage II or Stage III
- A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Breast Cancer
- Stage II-III
- OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I
- A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Early Stage
- Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Title Randomized Phase II Study of Sacituzumab Govitecan with or without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage II or Stage III
- A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1 Pilot Study with Dose Expansion of Chemotherapy in Combination with CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast Cancer (SCCC-03121)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-III
- A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 Inhibitor Therapy (OPERA-01)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Randomized, Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician’s Choice in Patients with AR+ Metastatic Triple-Negative or ER-Low Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab- paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TROPION -Breast05)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast CancerOptimizing Endocrine Therapy through Motivational Interviewing and Text Interventions
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Early Stage
- A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage 1
- A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) followed by Subcutaneous Trastuzumab versus Paclitaxel in Combination with Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT 2.0)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage 1
- A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Subcutaneous Pertuzumab, and Trastuzumab Fixed-Dose Combination for Patients with Anatomic Stage I Hormone Receptorpositive, HER2-Positive Breast Cancer (ADEPT)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-low Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Fuvedotin (BF; 9MW2821) in Subjects with Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated with Antibody-Drug Conjugates
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Colon/Rectal Cancer
- Stage II or Stage III
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Stage IV
An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib Plus Cetuximab with or without Chemotherapy Versus Standard of Care Therapy with a Safety Lead-In of Encorafenib and Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer.
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Gastric Cancer (Stomach Cancer)
- Randomized Phase III Trial of MFolfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IB - IIIC
- PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-Deletion
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Gynecologic Cancer
- Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer (AFT-50 - Endomap)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1/2 Study of REGN5668 (MUC16 X CD28, a Costimulatory Bispecific) Administered in Combination with Cemplumab or REGN4018 (MUC16 X CD3)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- RT-PACE: Phase I/II Study of Adjuvant Whole Pelvic Hypofractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-IV
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Head and Neck Cancer
- Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma that have Progressed after Platinum Treatment and Immunotherapy.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Study of Pembrolizumab in Combination with Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY trial (Squamous cell carcInoma of head and NEck Response-Guided therapY)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Study of Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Salivary Gland Carcinomas.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage III-IV
- Pilot Study of Induction Therapy Followed by Response-Adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab Versus Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 3 Open-Label Randomized Controlled Study to Evaluate Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Tx in Previously Treated Patients with Incurable Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Kidney Cancer
- Stage IV
- A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Leukemia
- Stage I - IV
- Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Liver Cancer
A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients with Advanced Hepatocellular Carcinoma (ITER-002-HCC)
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Lung Cancer
- Stage IIIB-IV
- Study Title A Phase 1B Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated Non-Small Cell Lung Cancer Whose Tumors have High PD-L1 Expression
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IIIB-C or Stage IV
- A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Randomized Phase 3 Study of Combination AZD9291 (Osimertinib) and Bevacizumab versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- Master Protocol to Evaluate Biomarker-Drive Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-II
- Phase III Randomized Placebo-Controlled Double-Blind Multi-Center International Study of Durvalumab with Stereotactic Body Radiation Therapy for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II Trial of Durvalumab (MEDI4736) and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I-III
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- Stage IIIB-IIIIC or Stage IV
- A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase Ib/IIa Safety and Tolerability Study of Bemcentinib with Pembrolizumab/ Carboplatin/ Pemetrexed in Subjects with Untreated Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) without/with a STK11 Mutation
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage I
- A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage II or IIIA, or IIIB (N2)
- A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IIIc – Stage IV
- A Phase III, Randomized, Open-Label Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Lymphoma
- Stage I - IV
- Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase I/II Study of Acalabrutinib, Venetoclax and Obinutuzimab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Multiple Myeloma
- A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Multiple Myeloma
- A Phase II Study of Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients with Relapsed Multiple Myeloma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Ovarian Cancer
- An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants with Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- CATALINA-2: A Phase 2 study evaluating the efficacy and safety of TORL-1-23 in women with Advanced platinum-resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Multi-Arm Phase 2 Study of Ubamatamab (REGN4018; MUC16xCD3 Bispecific Antibody) with or without Additional Agents in Platinum-Resistant Ovarian Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Pancreas Cancer
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Prostate Cancer
- A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients with High-Risk Localized Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- ProsGATE: Geriatric Assessment and Technology Evaluation in Prostate cancer.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III Randomized, Open-Label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE*)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- • A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Sarcoma
- A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Solid Tumors and Multiple Disease Sites
- Molecular Analysis for Combination Therapy Choice (ComboMATCH).
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IV
- A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-Expressing Tumors (DESTINY-PanTumor02)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Phase I/IIa Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-Expressing Cancers.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase I Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors.
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors (DB-1303-O-1001).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
Study Title An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations.
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1).
If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase I/II Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Stage IIB, IIIC, or Stage IV
- A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- Advanced Stage
- A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- • A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
- If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673).
- An Open-Label, Multicenter, Phase 1/1b Study of JANX008 In Subjects with Advanced or Metastatic Solid Tumor Malignancies
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-Cancer Agents in Patients with Advanced Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1/2A, Open-Label, Dose-Escalation and Dose-Expansion First-in-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) in Patients with Advanced Solid Organ Malignancies
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
- A Multicenter, Open-Label Phase 1/1b /Phase 2 Dose-Finding, Safety, And Pharmacokinetic Study Of MBRC-101, An Anti-Epha5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673).
Biobanking
- Protocol for Lymphoma Program Biobank
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
- Any Stage
- Genomic Analysis to Identify Correlates of the Inflamed Tumor-Phenotype in Patients with Advanced Malignancies Receiving Immunotherapy
- If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.